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Background: Advanced prostate cancer commonly metastasizes to bone leading to osteoblastic and osteolytic
lesions. Although an osteolytic component governed by activation of bone resorbing osteoclasts is prominent in
prostate cancer metastasis, the molecular mechanisms of prostate cancer-induced osteoclastogenesis are not
well-understood.
Methods: We studied the effect of soluble mediators released from human prostate carcinoma cells on osteoclast
formation from mouse bone marrow and RAW 264.7 monocytes.
Results: Soluble factors released from human prostate carcinoma cells significantly increased viability of naïve bone
marrow monocytes, as well as osteoclastogenesis from precursors primed with receptor activator of nuclear factor
κ-B ligand (RANKL). The prostate cancer-induced osteoclastogenesis was not mediated by RANKL as it was not
inhibited by osteoprotegerin (OPG). However inhibition of TGFβ receptor I (TβRI), or macrophage-colony stimulating
factor (MCSF) resulted in attenuation of prostate cancer-induced osteoclastogenesis. We characterized the signaling
pathways induced in osteoclast precursors by soluble mediators released from human prostate carcinoma cells.
Prostate cancer factors increased basal calcium levels and calcium fluctuations, induced nuclear localization of nu-
clear factor of activated t-cells (NFAT)c1, and activated prolonged phosphorylation of ERK1/2 in RANKL-primed
osteoclast precursors. Inhibition of calcium signaling, NFATc1 activation, and ERK1/2 phosphorylation significantly
reduced the ability of prostate cancer mediators to stimulate osteoclastogenesis.
Conclusions: This study reveals the molecular mechanisms underlying the direct osteoclastogenic effect of prostate
cancer derived factors, which may be beneficial in developing novel osteoclast-targeting therapeutic approaches.
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Prostate cancer is estimated to be the most common
cancer diagnosed in men in the United States [1], and the
sixth leading cause of cancer-related deaths in affected
men worldwide [2,3]. Autopsy studies have revealed that
over 80% of patients with advanced prostate cancer have
skeletal metastasis [4]. The growth-supportive interactions
between the disseminated prostate cancer cells and bone
induce heterogeneous lesions of mixed osteolytic and* Correspondence: svetlana.komarova@mcgill.ca
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article, unless otherwise stated.osteoblastic nature which disrupt bone homeostasis, lead-
ing to complications including spinal cord compression,
pathological fractures, and severe bone pain [5,6]. While
prostate cancer bone metastases were initially character-
ized to exhibit mainly osteoblastic lesions [7-10], studies
have revealed the clinical importance of the lytic compo-
nent of prostate cancer metastasizing to bone [11,12].
However the precise molecular basis underlying the ability
of prostate cancer cells to modulate bone resorption by
osteoclasts remains poorly understood.
Osteoclastogenesis is the differentiation of mono-
nuclear precursors originated from hematopoietic pro-
genitors of monocyte/macrophage lineage into mature
multi-nuclear resorbing osteoclasts [13,14]. RANKLCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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role in regulating osteoclastogenesis [15]. RANKL binds
to its receptor RANK and activates a signal transduction
cascade that leads to osteoclast differentiation in the
presence of MCSF, the osteoclast survival factor [16].
On the other hand, osteoprotegerin (OPG) produced by
osteoblasts acts as a decoy receptor for RANKL and
inhibits osteoclast formation [16,17]. MCSF is also pro-
duced by osteoblasts and is critically important for sur-
vival and differentiation of osteoclasts [13,14]. TGFβ
physiologically released from bone matrix also has an
ability to modify osteoclast differentiation and function
[18,19]. In particular, the presence of MCSF, TGFβ was
shown to induce osteoclast formation from mononuclear
precursors in a RANKL-independent manner [20].
When prostate cancer metastasizes to bone the normal
bone homeostasis is disrupted resulting in abnormal
stimulation of both osteoclastic and osteoblastic compo-
nents [21]. Targeting osteoclasts is clinically beneficial
for prostate cancer patients, since it has been shown that
the morbidity related to skeletal events is reduced when
prostate cancer patients are treated with denosumab, an
inhibitor for RANKL [22,23] or zoledronic acid, an in-
hibitor of osteoclastic activity [24]. However, blocking
RANKL does not completely block tumor development
and progression in bone tissue [25]. These findings suggest
that prostate cancer cells can produce other factors cap-
able of stimulating osteoclast formation and/or function.
This study focuses on characterizing the direct osteo-
clastogenic effects of soluble mediators released from
the prostate cancer cells, and the molecular signaling
pathways induced by prostate cancer factors in osteo-
clast precursors. We employed conditioned medium
(CM) as a source for factors produced by the human
prostate carcinoma cells, PC3 and LNCaP. In vivo stud-
ies have demonstrated that following injection of PC3 or
LNCaP cells in SCID mice, PC3 produces osteolytic
bone metastasis, while LNCaP leads to development of
osteolytic and osteoblastic bone lesions [26]. Mouse
bone marrow and RAW 264.7 murine monocytic cells
were used as the source of osteoclast precursors [27].
Methods
Cell lines and cultures
Human prostate cancer cell line, LNCaP was obtained
from the American Type Culture Collection (ATCC, VA,
USA; CRL-1740™) in October 2012, was expanded, frozen
in aliquots in liquid nitrogen and was used within first 3
passages from originally received cells. PC3 was kindly
provided by Dr. P.M. Seigel, McGill University, who re-
ceived it from Dr. Mario Chevrette (McGill University).
Prostate cancer cells were cultured in T-75 tissue culture
flasks at 37°C in 5% CO2 to 80% confluence in the incuba-
tion medium RPMI-1640 (350-000-CL, Wisent Inc.) withL-glutamine and sodium bicarbonate, supplemented with
1% sodium pyruvate (600-110-EL, Wisent Inc.), 1%
penicillin-streptomycin (450-201-EL, Wisent Inc.), and
10% fetal bovine serum (FBS, 080–150, Wisent Inc.). Pros-
tate cancer incubation medium not exposed to cells was
not capable to affect osteoclast formation (data not
shown). Cells were rinsed with serum-free medium, and
serum starved for 24 hours. CM (5.8 ± 0.6 ml/106 cells)
was collected, centrifuged (2000 RPM for 5 min), filtered
(0.22 μm), aliquoted, and stored at -80°C until use.
RAW 264.7 mouse monocytic cell line was obtained
from American Type Culture Collection, (ATCC; VA,
USA, TIB-71™), cultured at a density of 15 × 106 cells per
T-75 tissue culture flasks in incubation medium DMEM
(319-020-CL, Wisent Inc.) with 1.5 g/L sodium bicar-
bonate, 4.5 g/L glucose, supplemented with L-glutamine
(609-065-EL,Wisent Inc.), 1% sodium pyruvate, 1%
penicillin-streptomycin, and 10% FBS and was used
within first 3 passages from originally received cells. To
generate osteoclasts, RAW 264.7 monocytic cells were
seeded at a density of 5 × 103 cells/cm2. After 24 h, cell
cultures were supplemented with RANKL (50 ng/ml) for
2 days (priming) following by application of experimen-
tal stimuli, or RANKL for additional 2 days.
Animal studies for primary osteoclast cultures were
approved by the Animal Care Committee at the McGill
University and conformed to the ethical guidelines of
the Canadian Council on Animal Care and the Com-
mittee for Research and Ethical Issues of IASPe. Six
weeks old male Balb/c mice were purchased from
Charles River Co, euthanized, and their femora and
tibia were dissected free of soft tissues. Bone marrow
was collected from tibia and femora as previously de-
scribed [28]. Cells were cultured for 24 h at a density of
15 × 106 cells per T-75 tissue culture flasks in incuba-
tion medium α-MEM (12000–022, Gibco Life Tech)
supplemented with 1% penicillin-streptomycin, 1% so-
dium pyruvate, 2.2 g/L sodium bicarbonate (USP/FCC
Powder, Macron, 144-55-8), 10% FBS, 25 μg/ml MCSF
(300–25, Peprotech Inc.). Non-adherent cells were col-
lected, centrifuged, plated at a density of 7 × 104 cells/
cm2, and cultured in the presence of MCSF (50 ng/ml)
and RANKL (50 ng/ml) for 3 days (priming) following
by application of experimental stimuli, or RANKL for
additional 2 days.
Osteoclast identification
Osteoclast cultures were plated in 48-well plates, fixed
on day 5–6 with 10% formalin (23-245-685, Fisher) for
10 min at room temperature, and stained for tartrate-
resistant acid phosphatase (TRAP) by incubating for
30 min at 37°C in assay buffer (Sigma 387A). Osteoclasts
were identified as TRAP-positive dark-red/purple cells
with three or more nuclei. Images were recorded using a
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Reagents and antibodies
Recombinant human MCSF (300–25) was from Peprotech
Inc. Recombinant GST-RANKL which contains amino
acids 158–316 of the mouse RANKL gene was purified
from the clones kindly provided by Dr. M.F. Manolson,
University of Toronto. Human recombinant OPG (500 ng/
ml; amino acids 21–194 fused at the N-terminus to the Fc
domain of human IgG1, ab998, Abcam) was reconstituted
in PBS, aliquoted and stored at −80°C, and goat anti-
human anti-MCSF blocking antibody (5 μg/ml, AB-216-
NA, R&D systems) was reconstituted in PBS, aliquoted
and stored at −20°C. Serum free CM of prostate cancer
cells was pre-incubated with OPG and anti-MCSF for 30
and 60 min respectively, and added to the RANKL-primed
precursors. TGFβ type I receptor inhibitor (5 μM,
SB431542, Tocris Bioscience) was directly added to the
RANKL-primed precursors for 60 min before fresh
medium containing prostate cancer CM was applied.
Pharmacological inhibitor of MEK, PD98059 (100 μm for
RAW 264.7 and 50 μm for bone marrow cells, 513001,
Calbiochem), or NFAT inhibitor 11R-VIVIT peptide
(10 μm, 480401, Calbiochem) were added to RANKL-
primed precursors for 1 h before application of prostate
cancer CM. Calcium chelator BAPTA (50 μm, B6769, Invi-
trogen) was added to RANKL-primed precursors for
10 min at room temperature, then the cells were washed
with PBS, and the prostate cancer CM was applied. Inhibi-
tors were diluted in 0.1% DMSO (Sigma; D2650) which
was used as a vehicle.
Resorption assay
RAW 264.7 cells were seeded on calcium phosphate
plates (3989, Corning osteo assay), cultured for 2 days
with RANKL (50 ng/ml), then for 2 days with prostate
cancer CM or RANKL (50 ng/ml). The images of cul-
tures were recorded using a digital camera, and the cells
were removed using 0.2% TritonX-100 in 1 M NaCl to
visualize resorption pits.
Cell viability
RAW 264.7 cells were seeded in 96-well flat-bottomed
tissue culture plates (3595, Costar, Corning Inc) for 24 h,
and were cultured with the indicated experimental stim-
uli for 2 days. 10% AlamarBlue reagent (Carlsbad, CA,
USA, Invitrogen) was added to each well, and the plates
were incubated for additional 20 h. Fluorescence inten-
sity was measured using a plate reader (Infinite F200,
TECAN) with filter settings of excitation 560 nm and
emission 590 nm. Background reading obtained from
cell culture medium with no cells or treatments was
subtracted from all measurements.Immunoblotting
Cells were lysed in RIPA lysis buffer (50 mM Tris,
pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA,
1 mg/ml aprotinin, 2 mg/ml leupeptin, 0.1 mM phenyl-
methylsulfonyl fluoride, 20 mM sodium fluoride,
0.5 mM sodium orthovanadate), left on ice for 20 min,
and centrifuged at 12,000 × g for 10 min at 4°C. Super-
natant was collected, and protein content was deter-
mined using a Quant-iT™ protein assay kit (Invitrogen).
Whole cell lysates (50 μg) were resolved by SDS-PAGE
in 10% gel, and transferred onto a nitrocellulose trans-
fer membranes (0.45 μm, 162–0115, Bio-Rad) using
10 mM sodium tetraborate decahydrate (1303-96-4,
Fisher Scientific). The membranes were blocked with
5% non-fat dry milk for 1 h at room temperature in
TBS-T buffer (10 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 0.05% Tween 20) followed by overnight incuba-
tion at 4°C with primary antibodies: p-ERK1/2 (1:500,
9101, Cell Signaling), ERK1/2 (1:500, 9102, Cell Sig-
naling), or NFATc1 (1:200, 7A6, Santa Cruz Bio-
technology). The blots were washed, incubated with
horseradish peroxidase-conjugated secondary anti-
bodies (anti-mouse, 170–5047; anti-rabbit, 170–5046;
Bio-Rad), and visualized with a chemiluminescence sys-
tem (Super signal West Pico; 34080, Pierce). Blots were
re-probed with α-tubulin antibody (1:5000, T9026,
Sigma-Aldrich) as a loading control. Shown are repre-
sentation blots from 4 independent experiments.
Immunofluorescence
RAW 264.7 and bone marrow cells seeded on glass
cover-slips were primed with RANKL (50 ng/ml) for
2 days, and the experimental stimuli were applied for
additional 2 h. Samples were fixed in 10% formalin
(10 min at room temperature), washed with PBS-1X
(311-13-CL, Wisent Inc.); permeabilized in 0.1% Triton
X-100 diluted in PBS (10 min at room temperature),
washed three times with PBS, and incubated in 1% nor-
mal goat serum (NGS) blocking buffer (in PBS, AB-108-
C R & D System) overnight at 4°C. Monoclonal primary
antibody to NFATc1 (1:100 in NGS, Invitrogen), was
then added in blocking buffer at 4°C, for 24 h. After
washing three times with PBS, the coverslips were incu-
bated for 1 h at room temperature with the biotinylated
goat anti-mouse IgG (1:200 in NGS, Invitrogen), washed
three times with PBS and incubated for 1 h at room
temperature with Alexa Fluor 488 conjugated streptavidin
(1:100 in NGS, S11223, Invitrogen). For actin staining,
osteoclast cultures were stained with Alexa Fluor® 568
phalloidin (B3475, Invitrogen) for 1 h at room tem-
perature, washed two times with PBS. Nuclei were stained
using DAPI (1:5000 in distilled water, NL5995050, Invitro-
gen) for 1 min followed by two washes with distilled water.
Cover slips were mounted on slides using Immu-Mount
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inverted microscope (T2000, Nikon). For NFATc1 nuclear
localization analysis, five random images per experimental
condition were collected in each experiment, each image
containing 32 cells ± 18 for RAW 264.7 and 4 cells ±1 for
bone marrow precursors. Cells were rated positive for
nuclear localization of NFATc1 if fluorescence intensity of
nuclei exceeded that of the cytoplasm.Fluorescence measurements of cytosolic free Ca2+
concentration ([Ca2+]i)
RAW 264.7 cells were seeded on glass bottom 35-mm
dishes culture dishes (P35G-0-4-C MatTek Corp). After
2 days priming with 50 ng/ml RANKL, cells were
washed twice with DMEM containing 10 mM HEPES
(330-050-EL, Wisent Inc.), and incubated in dark with
1.5 μM fura-2-AM (F1221, Invitrogen) for 40 min, at
room temperature. Cultures were washed, and fresh
DMEM with 10 mM HEPES, containing no additions,
RANKL (50 ng/ml) or 10% prostate cancer CM were ap-
plied for 15 min, after which changes in calcium levels
were recorded for 120 s.Figure 1 Soluble factors produced by prostate cancer cells do not ind
increase the cell viability. RAW 264.7 monocytic cells were cultured for 4
positive control), or supplemented with 10% serum free CM from PC3 or LN
experimental setup for osteoclastogenesis assay from RAW 264.7 cells. B) R
osteoclast numbers formed in different cultures. Data are means ± SEM; n =
compared to untreated cells as assessed by Student’s t-test. D) RAW 264.7
or supplemented with 10% PC3 or LNCaP CM. The cells were then incubat
the average fluorescence intensity of viable cells subtracted from the readi
experiments; *P < 0.05 indicate significance compared to negative control aStatistical analyses
Data were presented as means ± standard error of the
mean (SEM), sample size (n) indicates the number of
independent experiments. Differences were assessed by
Student’s t-test or ANOVA for multiple group com-
parisons, and accepted as statistically significant at
p < 0.05.
Results
Soluble factors produced by prostate cancer cells do not
induce osteoclast formation from naïve monocytes, but
increased their viability
It was previously shown that prostate cancer cells pro-
duce factors that directly stimulate osteoclast formation
from naïve monocytes [5,29]. We cultured RAW 264.7
monocytes for 4 days untreated as negative control,
treated with RANKL (50 ng/ml) as positive control, or
supplemented with 10% serum free CM of prostate can-
cer cells, PC3 or LNCaP (Figure 1A). In negative control
cultures, RAW 264.7 cells formed only monocytic col-
onies. In positive control cultures, large multinucleated
osteoclasts were observed (Figure 1B, C). Prostate cancer
CM did not induce osteoclast formation from naïveuce osteoclast formation from naïve RAW 264.7 precursors but
days untreated (negative control), treated with 50 ng/ml RANKL (RL,
CaP, fixed, and stained for TRAP. A) Schematic overview of
epresentative images of cultures after 4 days of treatment. C) Average
10 independent experiments; ***P < 0.001 indicates significance
cells were cultured for 2 days untreated, treated with 50 ng/ml RANKL,
ed with AlamarBlue reagent for 20 h, and cell viability was assessed as
ngs obtained from the medium. Data are means ± SEM; n = 5
s assessed by Student’s t-test.
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cell density was visibly affected (Figure 1B). We directly
assessed cell viability of untreated, RANKL- or prostate
cancer CM-treated precursors, and have found that sol-
uble factors secreted by prostate cancer cells enhanced
monocyte viability (Figure 1D).
Soluble factors produced by prostate cancer cells induce
osteoclast formation from RANKL-primed osteoclast
precursors
We next assessed if factors secreted by prostate cancer
cells can augment osteoclast formation from RANKL-
primed osteoclast precursors. RAW 264.7 or bone mar-
row cells were treated with RANKL for a short period
of time: 2 days for RAW 264.7 or 3 days for bone mar-
row cells (we have found in preliminary experiments
that bone marrow cells require longer priming, sug-
gesting that they are less differentiated compared to
RAW264.7 cells). Then, the cells were cultured for
additional 2 days untreated (negative control), continu-
ously treated with RANKL (50 ng/ml, positive control)
or exposed to 10% of PC3 or LNCaP CM (Figure 2A, B).Figure 2 Soluble factors produced by prostate cancer cells increase o
Schematic overviews of experimental setup for osteoclastogenesis assay, fr
were first primed with 50 ng/ml RANKL (RL) for 2 days, and bone marrow c
untreated (negative control), treated with RANKL (positive control), or supple
osteoclasts formed in different conditions from RAW 264.7 (C), and bone m
conditions from RAW 264.7 (E) and bone marrow (F) cells. Data are means
cells; *P < 0.05, ***P < 0.001 indicate significance compared to negative conIn negative control cultures, only osteoclast precursors
and a few small osteoclasts were formed. In positive
control cultures, large multinucleated osteoclasts were
observed. Importantly, priming with RANKL resulted
in developing precursor sensitivity to soluble factors
produced by prostate cancer cells, evident in a sig-
nificant increase in numbers of large multinucleated
osteoclasts in PC3 and LNCaP CM-treated cultures
(Figure 2C-F).
We investigated the concentration-dependence of the
osteoclastogenic effect of the PC3 CM using different di-
lutions (5-50%) and found that when RANKL-primed
precursor cultures were supplemented with 5-10% PC3
CM, osteoclast number was significantly increased. Fur-
ther increase in the PC3 CM from 10 to 50% resulted in
decline in osteoclastogenic efficiency, possibly reflecting
depletion of nutrients in the medium due to condition-
ing by the PC3 cells (Figure 3A). Osteoclasts induced by
prostate cancer CM exhibited characteristic features of
functional resorptive cells such as actin rings associated
with resorption (Figure 3B), and were capable of resorb-
ing mineralized matrices (Figure 3C).steoclast formation from RANKL-primed precursors. A, B)
om (A) RAW 264.7 and (B) bone marrow cells. RAW 264.7 monocytes
ells for 3 days; then the osteoclast precursors (Pre-OC) were cultured
mented with 10% PC3 or LNCaP CM. C, D) Representative images of
arrow (D) cells. E, F) Average osteoclast numbers formed in different
± SEM; n = 10 experiments for RAW 264.7 cells, n = 7 for bone marrow
trol as assessed by Student’s t-test.
Figure 3 Osteoclasts are induced by prostate cancer CM in a concentration-dependent manner, exhibit characteristic actin structure,
and resorb calcified matrices. A) RAW 264.7 cells were first primed with 50 ng/ml RANKL for 2 days, then cultured for additional 2 days
untreated (negative control), or exposed to different dilutions of PC3 CM , and the average number of osteoclasts was assessed. Data are means ±
SEM; n = 3-10 experiments; *P < 0.05, ***P < 0.001 indicate significance compared to negative control as assessed by ANOVA following by Tukey
posttest. B) RANKL-primed osteoclast precursors supplemented for 2 days with 10% CM of PC3 (top) or LNCaP (bottom) were fixed, actin filaments
were labeled using Alexa Fluor® 568 phalloidin (red), and nuclei were counterstained with DAPI (blue). Representative images of actin rings in
osteoclasts formed after exposure to prostate cancer CM. C) RAW 264.7 cells were placed on calcium phosphate substrates, primed with RANKL for
2 days, and exposed to 10% PC3 (top) or LNCaP (bottom) CM for 2 days. Top: Representative image of active multinucleated osteoclast (red arrow)
forming a resorption pit (red outline). Bottom: Representative image of resorbed areas after osteoclasts were removed.
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by prostate cancer cells is not mediated by RANKL
We investigated if the effects of prostate cancer CM may
be mediated by RANKL produced by prostate cancer cells.
We pre-incubated prostate cancer CM with RANKL decoy
receptor OPG (500 ng/ml), and then added to the RANKL-
primed precursors. OPG did not attenuate osteoclastogenic
effect of PC3 or LNCaP CM in RANKL-primed RAW
264.7 (Figure 4A and B), or bone marrow cells (Figure 4D
and E). At the same time, when added at the same concen-
tration OPG dramatically inhibited RANKL-induced osteo-
clastogenesis (Figure 4). These data indicate that soluble
factors produced by prostate cancer cells induce osteoclast
formation in RANKL independent manner.
We next assessed if anti-MCSF blocking antibody will
affect the action of prostate cancer on osteoclast formation.
Prostate cancer CM was pre-incubated with anti-MCSF
blocking antibody (5 μg/ml) and then added to the RANKL-
primed precursors from bone marrow. We have found that
blocking MCSF significantly attenuated the effect of prostate
cancer CM on osteoclastogenesis (Figure 4D and E).
We examined the involvement of TβRI in prostate can-
cer induced osteoclastogenesis, by using pharmacological
inhibitor of TβRI kinase inhibitor. RANKL-primed bone
marrow precursors were cultured with prostate cancer
CM in presence and absence of TβRI kinase inhibitor or
vehicle (DMSO, 0.1%). Inhibition of TβRI significantly de-
creased prostate cancer CM-induced osteoclast formation
from RANKL-primed precursors (Figure 4D and E).
Soluble factors produced by prostate cancer cells induce
calcium/NFATc1 signaling in osteoclast precursors
Calcium signaling has been shown to be critical for
both RANKL [30], and breast cancer factors-inducedosteoclastogenesis from RANKL-primed osteoclast pre-
cursors [28,31]. RANKL-primed RAW 264.7 cells were
loaded with a calcium-sensitive dye fura-2-AM, washed
and incubated for 15 min in fresh media containing no
additions, RANKL (50 ng/ml), or 10% prostate cancer
CM. Changes in cytosolic free calcium concentration
([Ca2+]i) were recorded for 120 s. We assessed average
basal calcium levels over 120 s, and fluctuations in basal
levels (known to be important for osteoclastogenesis) as
standard deviation of basal levels. The precursor was
considered to be “active” if the standard deviation
exceeded that of 0.05 ratio units. We have found that
addition of RANKL or 10% of PC3 or LNCaP CM to
RANKL-primed precursors significantly increased aver-
age basal calcium level (Figure 5A), as well as the per-
centage of active cells in the population (Figure 5B). To
assess if calcium signaling is important for osteoclasto-
genesis induced by prostate cancer CM, we pretreated
RANKL-primed bone marrow precursors with vehicle
(DMSO) or calcium chelator BAPTA for 10 min,
washed and supplemented with 10% prostate cancer
CM for 2 days. Inhibition of calcium signaling using
BAPTA significantly impaired the ability of PC3 or
LNCaP CM to induce osteoclast formation (Figure 5C).
Since NFATc1 is a calcium-dependent osteoclastogenic
transcription factor, highly up-regulated during osteo-
clast formation [30,32], and involved in breast cancer-
induced osteoclastogenesis [33]; we next examined if
NFATc1 mediates the osteoclastogenic effects of prostate
cancer CM. We investigated the effect of prostate cancer
CM on NFATc1 protein expression levels and cellular
localization in RANKL-primed precursors exposed to
prostate cancer CM for 2 h. While priming with RANKL
resulted in significant increase in NFATc1 protein levels,
Figure 4 Soluble factors produced by prostate cancer cells increase osteoclast formation in RANKL-independent manner. A, B) RAW
264.7 cells were primed with RANKL for 2 days, then cultured for 2 days untreated (negative control), with RANKL (positive control) or exposed to
10% PC3 or LNCaP CM, in the absence (black bars) or presence of 500 ng/ml OPG (white bars), and the average number of osteoclasts was
assessed. A) Representative images of osteoclasts induced by RANKL or prostate cancer CM in the absence (top), or presence (bottom) of OPG. B)
Average number of osteoclasts formed in different conditions. Data are means ± SEM; n = 4-10 experiments, except for RANKL and OPG, where
n = 2 repeats. C-E) Bone marrow cells were primed with RANKL for 3 days, and cultured for 2 days untreated (negative control), treated with
RANKL (positive control) (C) or exposed to 10% CM of PC3 (D) or LNCaP (E) cells, in the absence (black bars), or presence of 500 ng/ml OPG
(white bars), or 5 μg/ml anti-MCSF blocking antibody (light gray bars) or TβRI inhibitor (5 μM, dark gray bars) and the average osteoclast numbers
were assessed. OPG and anti-MCSF were added to prostate cancer CM for 30–60 min prior to addition to osteoclast precursors, TβRI inhibitor was
added to the osteoclast precursor cultures for 60 min prior to addition of prostate cancer CM. Data are means ± SEM; n = 3-7 experiments. *P < 0.05,
***P < 0.001 indicate significance compared to negative control; #P < 0.05, ###P < 0.005 indicate significance as compared to no inhibitor as assessed by
Student’s t-test, no significant difference between samples treated with CM with and without OPG.
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(Figure 5D). Using immunofluorescence, we assessed
NFATc1 localization. When RANKL-primed precursors
were cultured for 2 h without RANKL, only 22-30% of
precursors exhibited nuclear localization of NFATc1
(Figure 6E-G). In contrast, 42-90% of osteoclast precur-
sors exhibited nuclear NFATc1 in cultures continuously
treated with RANKL. Exposure of RANKL-primed pre-
cursors to 10% prostate cancer CM resulted in signifi-
cant increase in the percentage of precursors (69-97%
for PC3, 80-93% for LNCaP) exhibiting nuclear NFATc1
compared to negative control (Figure 6E-G).
To further confirm that the effect of prostate cancer
CM on osteoclastogenesis is mediated by NFATc1 nu-
clear translocation, we pretreated RANKL-primed bone
marrow precursors for 1 h with vehicle (DMSO) or
NFAT inhibitor, VIVIT. Prostate cancer CM-induced
NFATc1 nuclear translocation was attenuated by VIVIT
(Figure 6G). Osteoclast formation induced by prostate
cancer CM was significantly reduced in RANKL-primedbone marrow precursors exposed to VIVIT compared to
control (Figure 6H). Thus, prostate cancer-derived fac-
tors can substitute for RANKL in maintaining calcium
signaling and NFATc1 activity.
Soluble factors produced by prostate cancer cells induce
osteoclastogenesis through activation of MEK/ERK
signaling pathway
ERK activation induced by RANKL is known to be in-
volved in osteoclastogenesis [34]. To investigate if ERK
activation is involved in prostate cancer CM-induced
osteoclastogenesis, we cultured RANKL-primed RAW
264.7 osteoclast precursors untreated, treated with
RANKL (50 ng/ml), or supplemented with 10% PC3 or
LNCaP CM for 5–60 min. Whole cell extracts were col-
lected and ERK1/2 phosphorylation was assessed using
immunoblotting against p-ERK1/2 (Figure 6A, top row).
Total ERK1/2 (Figure 6A, middle row) and α-tubulin
(Figure 6A, bottom row) were used as internal and load-
ing controls respectively. Prostate cancer CM induced
Figure 5 Prostate cancer-derived factors induce calcium/NFATc1 signaling in osteoclast precursors. A, B) RANKL-primed RAW 264.7 cells
were loaded with fura-2-AM, cultured for 15 min untreated (negative control), with 50 ng/ml RANKL, or 10% PC3 or LNCaP CM, and imaged for 2
min. A) Average basal calcium levels. Data are means ± SD; n = 32-48 cells per condition; *significance compared to negative control as assessed
by Student’s t-test. B) Percentage of active cells classified as having standard deviation of basal calcium above 0.05. C) RANKL-primed bone marrow
precursors were pre-treated with 50 μM BAPTA (white bars) and exposed to 10% PC3 or LNCaP CM for 2 days, and average number of osteoclasts was
assessed. Data are means ± SEM; n = 3-7 experiments; *significance compared to negative control; #significance compared to no inhibitor. D, F) Protein
was extracted or samples were fixed from untreated or RANKL-primed RAW 264.7 cells, or RANKL-primed precursors cultured for 2 h untreated, with
RANKL, or with 10% PC3 or LNCaP CM. D) NFATc1 protein levels, α-tubulin as a loading control. E) NFATc1 localization (green); nuclei were counterstained
using DAPI (blue). F) Average NFATc1 nuclear localization normalized to the continuous RANKL (RL) treatment. Data are means ± SEM; n = 3 experiments.
G, H) RANKL-primed bone marrow cells were pretreated with 0.1% DMSO vehicle (grey bars), or 50 μM NFAT inhibitor VIVIT (white bars), and cultured
untreated, treated with RANKL, or with 10% PC3 or LNCaP CM for 2 h to examine NFATc1 localization; or 2 days to assess osteoclast formation. G) Average
percentage of cells with nuclear NFATc1. Data are means ± SEM; n = 3 experiments. H) Average number of osteoclasts. Data are means ± SEM; n = 3-7
experiments; *significance compared to negative control, #significance as compared to no inhibitor.
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http://www.biomedcentral.com/1471-2407/13/605prolonged ERK1/2 phosphorylation that became evident
at 15 min, reached maximum at 30 min, and was
maintained after 60 min. ERK1/2 total levels were not
affected by the treatments. Pretreatment of RANKL-
primed RAW 264.7 precursors with pharmacological
inhibitor of MEK1/2, PD98059 attenuated ERK1/2 acti-
vation both at 30 and 60 min after exposure to prostate
cancer CM (Figure 6B). Inhibition of ERK1/2 phosp-
horylation significantly impaired prostate cancer CM-
induced osteoclastogenesis from RAW 264.7 and bone
marrow precursors (Figure 6C-E). In contrast, MEK1/2
inhibitor had only small impact on RANKL induced
osteoclast formation (Figure 6C). These data suggest
that soluble factors produced by prostate cancer cells
induce osteoclastogenesis through activation of MEK/
ERK pathway.Discussion
This study reports that soluble factors produced by pros-
tate cancer cells directly induced osteoclast formation
from precursors primed with RANKL for a short period
of time. In contrast, prostate cancer-derived factors were
not capable of inducing osteoclast formation from naïve
precursors. We have found that while RANKL was im-
portant to convey sensitivity to cancer derived factors
for osteoclast precursors, the subsequent osteoclast for-
mation was not mediated by RANKL. Our data demon-
strate that soluble factors produced by prostate cancer
cells induce osteoclast formation through activation of
calcium/NFATc1 and MEK/ERK signaling pathways.
Previous studies have revealed that factors produced
by prostate cancer cells directly induce osteoclastogene-
sis in both RANKL-dependent [21,29], and RANKL-
Figure 6 Prostate cancer-derived factors induce activation of MEK/ERK pathway in osteoclast precursors. A) RANKL-primed RAW 264.7
cells were cultured for 5–60 min untreated (negative control), treated with RANKL, or exposed to 10% PC3 or LNCaP CM. Total protein was
extracted and the levels of phosphorylated ERK1/2 (p-ERK1/2), total ERK1/2, and α-tubulin were assessed by immunoblotting. B) RANKL-primed RAW
264.7 cells were pretreated for 1 h with 0.1% DMSO vehicle, or 100 μM MEK inhibitor (PD98059), washed and cultured for 30–60 min untreated, treated
with RANKL, or 10% PC3 or LNCaP CM. Total protein was extracted and immunoblotted for p-ERK1/2, total ERK1/2 and α-tubulin. C-E) RANKL-primed
RAW 264.7 (C-D), or bone marrow (E) cells were pretreated for 1 h with 0.1%, DMSO vehicle (gray bars), or MEK inhibitor, 100 μM for RAW 264.7 and
50 μM for bone marrow cells (white bar), washed and cultured for 2 days (negative control), treated with RANKL, or 10% PC3 or LNCaP (right column),
and the average osteoclast numbers were assessed. C) Representative images of osteoclasts formed from RAW 264.7 cells in different conditions. D-E)
Average number of osteoclasts formed in RAW 264.7 (D) or bone marrow (E) cultures at different conditions. Data are means ± SEM; n = 4-10
experiments for RAW 264.7 cells, n = 3-7 experiments for bone marrow cells; *P < 0.05, ***P < 0.001 indicate significance compared to negative control;
#P < 0.05, ##P < 0.01, ###P < 0.001 compared to no inhibitor, assessed by Student’s t-test.
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have been shown to produce soluble RANKL [21,35],
the amount was measured to be 10-fold lower than the
levels produced by osteoblasts [5]. It is difficult to dir-
ectly compare the results obtained in different studies,
because different osteoclastogenic assays as well as con-
ditioned medium preparations were used. In addition, it
has been now recognized that cell lines, including pros-
tate cancer and monocytic cells exhibit significant
heterogeneity [36-39]. The main difference between our
study and the previous ones is that we did not observe
osteoclastogenesis when prostate cancer CM was ap-
plied to naïve osteoclast precursors. In contrast, we
have found that cell viability of precursors was signifi-
cantly improved in the presence of prostate cancer
factors, which could potentially contribute to increasedosteoclastogenesis in different osteoclastogenesis assay.
In our study, prostate cancer factors were not able to
induce osteoclastogenesis unless monocyte precursors
were first primed with RANKL for 2–3 days. These data
are similar to the effects of breast cancer cells on osteo-
clast formation [31,33,40], which were also found to
occur in a RANKL-independent manner. Thus, our
study suggests that RANKL is important in cancer-
induced osteoclastogenesis for the initial priming of
osteoclast precursors; however, in the later stages osteo-
clastogenesis can proceed without RANKL, providing an
explanation for the lack of complete inhibition of osteo-
clast numbers after blocking RANKL signaling [41].
Exposure to prostate cancer factors results in formation
of functional osteoclasts, evident by the presence of large
osteoclast actin rings that are indicative of formation of
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lished at sites of osteoclast attachment to the bone surface
[42,43]. Importantly, osteoclasts formed in the presence of
prostate cancer cells were capable of resorbing mineral-
ized matrices. We observed that only 5 to 10% dilutions of
prostate cancer CM were capable to induce osteoclasto-
genesis from RANKL-primed RAW 264.7 precursors,
while further increase in the amount of prostate cancer
CM (20 to 50%) resulted in blunting the osteoclastogenic
effects of CM. This may be consequent to the depletion of
nutrients in prostate cancer CM, or to the presence of dif-
ferent active ingredients with competing actions.
We have demonstrated that prostate cancer factors in-
duce osteoclastogenesis from late precursors in a
RANKL-independent manner. Inhibition of TGFβ sig-
naling in osteoclast precursors or depletion of MCSF in
prostate cancer CM significantly attenuated osteoclasto-
genesis. TGFβ signaling has a key role in enhancing can-
cer progression and cancer induced bone metastasis
[33,44]. Inhibition of TGFβ signaling in the mouse
model of osteoblastic bone metastasis resulted in signifi-
cant decrease in tumor incidence [45], however it was
mostly attributed to the effects of TGFβ on osteoblasts.
Importantly, PC3 and LNCaP prostate cancer cells has
been shown to produce very low amounts of TGFβ
[46,47], 10-100 times less than TGFβ levels reported in
the fetal bovine serum by Thermo Scietific (www.ther-
moscientific.com) in December 2013, leading to the sug-
gestion that in vitro cancer cells are more likely to act
through activating TGFβ present in serum [46]. MCSF
was reported to promote mature osteoclast survival and
motility [48], and recently activation of mature osteo-
clasts, bone resorption [49]. Thus, our data suggest
that TGFβ and MCSF may synergize with other soluble
factors produced by prostate cancer in inducing
osteoclastogenesis.
To characterize the signaling pathways induced in
osteoclast precursors by prostate cancer cells, we first
examined calcium/NFATc1 signaling. It has been well
documented that RANKL stimulates calcium oscilla-
tions, resulting in sustained activation and up regulation
of NFATc1 required for osteoclast differentiation [30,32].
In addition, we have previously shown that breast cancer
cells produce factors capable of inducing calcium signal-
ing and maintaining NFATc1 activation in RANKL-
primed osteoclast precursors [28,31,33]. In this study,
we demonstrated that soluble factors produced by pros-
tate cancer increase basal calcium as well as the propor-
tion of cells with active fluctuations in calcium levels in
RANKL-primed osteoclast precursors. Moreover, block-
ing changes in [Ca2+]i using intracellular chelator
BAPTA prevented the osteoclastogenic effects of pros-
tate cancer factors. RANKL is known to strongly up-
regulate protein expression of NFATc1, which wasrecognized as an essential osteoclastogenic transcription
factor [30]. Inactive NFATc1 is maintained in the cytosol
in a hyper-phosphorylated form. Activation and nuclear
translocation of NFATc1 requires stimulation of phos-
phatase calcineurin, which is in turn activated by calcium
signaling [30,50]. We have found that in RANKL-primed
precursors NFATc1 protein levels were significantly in-
creased compared to naïve precursors, and were not af-
fected by exposure to prostate cancer CM. In contrast,
nuclear localization of NFATc1 was highly sensitive to
the presence of RANKL, and was effectively maintained
by prostate cancer factors. Inhibition of NFATc1 using
cell-permeable peptide inhibitor VIVIT significantly in-
terfered with the ability of prostate cancer-derived factors
to induce osteoclastogenesis. Thus, prostate cancer fac-
tors were found to induce calcium signaling supporting
NFATc1 activation in RANKL-primed osteoclast precur-
sors. It is likely that induction of NFATc1 expression that
occurred during priming of osteoclast precursors with
RANKL was necessary for acquisition of their sensitivity
to prostate cancer factors.
In addition to the calcium/NFATc1 signaling pathways,
we have demonstrated that soluble factors produced by
prostate cancer cells also promoted ERK1/2 activation.
We have found that prostate cancer factors induce pro-
longed phosphorylation of ERK1/2, which was abolished
by MEK1/2 inhibitor PD98059. Importantly, osteoclasto-
genesis induced by prostate cancer factors was drastic-
ally reduced when MEK/ERK activation was prevented
by PD98059. MAP kinases have been previously shown
to play an important role in osteoclast formation and
functions [34,51]. However, in our study inhibition of
ERK1/2 had only minor effect on RANKL-induced oste-
oclastogenesis, which is consistent with published find-
ings [50]. While we have previously shown that breast
cancer factors also induce ERK1/2 phosphorylation act-
ing through TGFβ-dependent and independent mecha-
nisms, inhibition of MEK was not effective in preventing
breast cancer factors-induced osteoclastogenesis [31].
Thus, activation of MEK/ERK signaling pathway exhib-
ited features unique to the osteoclastogenic effects of
soluble factors produced by prostate cancer cells.
Conclusions
This study reveals the molecular mechanisms underlying
the direct osteoclastogenic effect of prostate cancer de-
rived factors on osteoclast precursors. Although strong
osteoclast targeting therapies, including bisphosphonates
[24] and RANKL-targeting denosumab [22,23] are
already used to treat patients with bone metastases ori-
ginating from prostate cancer, drug resistance or intoler-
ance compels the continued search of new treatments.
Since both breast and prostate cancer patients suffer
from frequent bone metastases, it is important to
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interactions of breast and prostate cancer cells with bone
microenvironment. We have found that many prostate
cancer-induced osteoclast signaling pathways were similar
to those induced by breast cancer factors, supporting the
notion that specific targeting of osteoclastogenic signaling
can be effective to treat both breast and prostate cancer
metastasis to bone, even if the mediators produced by
these cancers are different. In addition, we have identified
ERK1/2 as a unique target employed by prostate cancer
cells to induce osteoclastogenesis.
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